Literature DB >> 2228320

Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies.

S Reber1, S Matzku, U Günthert, H Ponta, P Herrlich, M Zöller.   

Abstract

The influence of 4 murine monoclonal antibodies (MAbs) directed against surface determinants of a metastasizing rat adenocarcinoma (BSp73ASML) on metastatic spread was evaluated and compared to their in vivo binding as well as to the induction of a humoral anti-MAb response, especially with respect to the development of anti-idiotypic (ID) antibodies of the internal image type. In a protocol of explicit immunization, all 4 MAbs transiently inhibited metastatic growth. Survival was prolonged only with one MAb (4.4ASML). With another MAb (1.1ASML), directed against a new variant form of CD44, metastatic growth was accelerated after transient retardation. Retardation of metastatic growth correlated with the humoral anti-MAb response. This accounted for the isotype- as well as for the idiotype-specific response. An exception was noted after immunization with MAb 1.1ASML. Rats with high levels of anti-1.1ASML antibodies, which inhibited binding to the tumor cells (internal image-type antibodies) showed accelerated metastatic spread. Data are interpreted to mean that MAb-induced inhibition of metastatic spread may be based on 2 independent mechanisms: blockade of metastasis-associated epitopes (i.e., with MAb 1.1ASML) and induction of an anti-mouse Ig response. In the latter case it was irrelevant whether the response was isotype- or idiotype-specific.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228320     DOI: 10.1002/ijc.2910460528

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation.

Authors:  Ulrich Richter; Daniel Wicklein; Silvana Geleff; Udo Schumacher
Journal:  Histochem Cell Biol       Date:  2012-01-24       Impact factor: 4.304

Review 2.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

3.  Clinical significance of CD44v mRNA detection by PCR in peripheral blood of patients with hepatocellular carcinoma.

Authors:  P F Liu; M C Wu; H Cheng; G X Qian; J L Fu
Journal:  World J Gastroenterol       Date:  1997-12-15       Impact factor: 5.742

4.  Splicing choice from ten variant exons establishes CD44 variability.

Authors:  C Tölg; M Hofmann; P Herrlich; H Ponta
Journal:  Nucleic Acids Res       Date:  1993-03-11       Impact factor: 16.971

5.  A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth.

Authors:  L Sherman; D Wainwright; H Ponta; P Herrlich
Journal:  Genes Dev       Date:  1998-04-01       Impact factor: 11.361

Review 6.  CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation.

Authors:  M Zöller
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

7.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

8.  CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues.

Authors:  H J Terpe; H Stark; P Prehm; U Günthert
Journal:  Histochemistry       Date:  1994-02

9.  EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.

Authors:  Moutushy Mitra; Mallikarjuna Kandalam; Anju Harilal; Rama Shenkar Verma; Uma Maheswari Krishnan; Sethuraman Swaminathan; Subramanian Krishnakumar
Journal:  Mol Vis       Date:  2012-02-01       Impact factor: 2.367

10.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.